Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients

European Journal of Haematology

Volumn 91, Issue 3, 2013, Pages 249-261

  Lu, Wenyi ^a   Zhao, Mingfeng ^a   Rajbhandary, Sajin ^a   Xie, Fang ^a   Chai, Xiao ^a   Mu, Juan ^a   Meng, Juanxia ^a   Liu, Yongjun ^b   Jiang, Yan ^a   Xu, Xinnv ^c   Meng, Aimin ^d  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c TIANJIN FIRST CENTRAL HOSPITAL   (China)

^d INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Hematopoiesis; Iron overload; Mesenchymal stem cell; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; CD34 ANTIGEN; DEFEROXAMINE; FERRIC AMMONIUM CITRATE; FERRITIN; IRON; REACTIVE OXYGEN METABOLITE; TRANSFERRIN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CATALYSIS; CHELATION THERAPY; CLINICAL ARTICLE; COCULTURE; COLONY FORMING CELL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FLOW CYTOMETRY; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON OVERLOAD; MALE; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPHIL COUNT; OXIDATIVE STRESS; PANCYTOPENIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT RESPONSE; WESTERN BLOTTING;

HEMATOPOIESIS; IRON OVERLOAD; MESENCHYMAL STEM CELL; REACTIVE OXYGEN SPECIES;

ADULT; AGED; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DEFEROXAMINE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IRON; IRON OVERLOAD; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84881669596     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12159     Document Type: Article

References (36)

1. Lee SE, Yahng SA, Cho BS, et al. Improvement in hematopoiesis after iron chelation therapy with Deferasirox in patients with aplastic anemia. Acta Haematol 2012;129:72-7.
2. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288-99.
3. Guariglia R, Martorelli MC, Villani O, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 2011;35:566-70.
4. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA. Changes in parameters of oxidative stress and free iron biomarkers during treatment with Deferasirox in iron-overloaded patients with Myelodysplastic syndromes. Haematologica 2010;95:1433-4.
5. Ferro E, Visalli G, Civa R, La Rosa MA, Randazzo Papa G, Baluce B, D'Ascola DG, Piraino B, Salpietro C, Di Pietro A. Oxidative damage and genotoxicity biomarkers in transfused and untransfused thalassemic subjects. Free Radic Biol Med 2012;53:1829-37.
6. Kikuchi S, Kobune M, Iyama S, et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med 2012;53:643-8.
7. Tothova Z, Kollipara R, Huntly BJ, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007;128:325-39.
8. Heo JY, Jing K, Song KS, et al. Downregulation of APE1/Ref-1 Is involved in the senescence of mesenchymal stem cells. Stem Cells 2009;27:1455-62.
9. Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 2007;11:3056-63.
10. Shao L, Li H, Pazhanisamy SK, Meng A, Wang Y, Zhou D. Reactive oxygen species and hematopoietic stem cell senescence. Int J Hematol 2011;94:24-32.
11. Chen CT, Shih YR, Kuo TK, Lee OK, Wei YH. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 2008;26:960-8.
12. Frippiat C, Dewelle J, Remacle J, Toussaint O. Signal transduction in H2O2-induced senescence-like phenotype in human diploid fibroblasts. Free Radic Biol Med 2002;33:1334-46.
13. Prus E, Fibach E. Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells. Acta Haematol 2010;123:14-20.
14. Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, Hangaishi A, Kurokawa M. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol 2012;95:149-59.
15. Zhao MF, Xie F, Li YM, et al. Increased intracellular concentration of reactive oxygen species mediated the deficient hematopoiesis of iron overload bone marrow. Blood 2010;116:4247a. (ASH Annual Meeting Abstracts).
16. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press 2001;61-73.
17. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia. J Clin Oncol 1999;17:3835-49.
18. Piperno A. Classification and diagnosis of iron overload. Haematologica 1998;83:447-55.
19. Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL, EPIC study investigators. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol 2011;87:338-48.
20. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
21. Prus E, Fibach E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A 2008;73:22-7.
22. Kumar BM, Yoo JG, Ock SA, et al. In vitro differentiation of mesenchymal progenitor cells derived from porcine umbilical cord blood. Mol Cells 2007;24:343-50.
23. Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Transfusion 2008;48:2638-44.
24. Hammoud M, Vlaski M, Duchez P, Chevaleyre J, Lafarge X, Boiron JM, Praloran V, Brunet De La Grange P, Lvanovic Z. Combination of low O(2) concentration and mesenchymal stromal cells during culture of cord blood CD34(+) cells improves the maintenance and proliferative capacity of hematopoietic stem cells. J Cell Physiol 2012;227:2750-8.
25. Hartmann J, Sinzig U, Wulf G, Truemper LH, Braulke F, Konietscheke F, Haase D. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS. Blood 2008;112:2694a. (ASH Annual Meeting Abstracts).
26. Saigo K, Takenokuchi M, Hiramatsu Y, Tada H, Hishita T, Takata M, Misawa M, Imoto S, Imashuku S. Oxidative stress levels in MDS patients: their relationship to serum ferrtin and haemoglobin value. J Int Med Res 2011;39:1941-5.
27. Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica 2012;97:1364-71.
28. Juvonen E, Sahlstedt L, Parrkinen J, Ruutu T. Inhibition of erythroid and granulocyte-macrophage colony formation by non-transferrin-bound iron in vitro: protective effect of apotransferrin. Eur J Haemotol 2007;79:126-31.
29. Gattermann N. The role of mitochondria in MDS. In: Steensma DP, ed. Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York: Informa Healthcare Ltd; 2009:127-51.
30. Urao N, Ushio-Fukai M. Redox regulation of stem/progenitor cells and bone marrow niche. Free Radic Biol Med 2013;54:26-39.
31. Jomova K, Valko M. Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des 2011;17:3460-73.
32. Zhang DY, Wang HJ, Tan YZ. Wnt/β-catenin signaling induces the aging of mesenchymal stem cells through the DNA damage response and the p53/p21 pathway. PLoS ONE 2011;6:e21397.
33. Clopton DA, Saltman P. Low-level oxidative stress causes cell-cycle specific arrest in cultured cells. Biochem Biophys Res Commun 1995;210:189-96.
34. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006;12:446-51.
35. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000;28:1387-404.
36. Pietras EM, Warr MR, Passegue E. Cell cycle regulation in hematopoietic stem cells. J Cell Biol 2011;195:709-20.